SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311621 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jin-Young Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genomic Instability and Cancer Therapeutics, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Recombinational DNA Repair, Breast Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science.
Abstract (Originalsprache)
While PARP inhibitors like Olaparib are effective against BRCA1-deficient breast cancers, their efficacy in BRCA1-proficient tumors depends on the functional status of homologous recombination (HR) repair. Here, we identify the structure-specific endonuclease SLX1 as a key regulator of HR and a determinant of Olaparib sensitivity in BRCA1-intact breast cancer. SLX1 is frequently upregulated in breast cancer and associated with poor prognosis. Functional studies revealed that SLX1 promotes RAD51-mediated HR repair of DNA double-strand breaks. Consequently, SLX1 depletion reduces HR efficiency, increases chromosomal instability, and sensitizes breast-proficient breast cancer cells to DNA-damaging agents, including camptothecin, ionizing radiation, and Olaparib. In contrast, SLX1 overexpression enhances DNA repair capacity and promotes Olaparib resistance. In vivo, SLX1 knockdown synergizes with Olaparib to suppress tumor growth in xenograft models. These findings establish SLX1 as a critical regulator of HR function in BRCA1-proficient breast cancer and a promising target for restoring PARP inhibitor sensitivity through induced HR deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Genomic Instability and Cancer Therapeutics, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
- Department of Cellular and Molecular Medicine, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
- Department of Pharmacology, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
- Department of Anatomy, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
- Department of Hemato-Oncology, Chosun University Hospital Internal Medicine, Gwangju 61453, Republic of Korea.
ORCID-Profile: Young Jin Jeon
Förderung
- National Research Foundation of Korea
- Ministry of Science
Zitieren
APA
Kim, J. Y., Kim, J., Chang, I. Y., Park, S. G., You, H. J., Jeon, Y. J., & Lee, J. H. (2025). SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311621
Vancouver
Kim JY, Kim J, Chang IY, Park SG, You HJ, Jeon YJ, et al. SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311621
BibTeX
@article{Kim2025,
author = {Kim, Jin-Young and Kim, Jeeho and Chang, In-Youb and Park, Sang-Gon and You, Ho Jin and Jeon, Young Jin and Lee, Jung-Hee},
title = {SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311621}
}
EUVIMED